Beyond Air (XAIR) CFO purchases common stock plus Series A and B Warrants
Rhea-AI Filing Summary
Beyond Air, Inc. Chief Financial Officer Daniel J. Moorhead reported purchases on 2026-07-29 of 4,340 shares of common stock at $5.76 per share, along with 4,340 Series A Warrants and 4,340 Series B Warrants, each exercisable for common stock at $5.51 per share. The Series A Warrants are exercisable immediately and expire on the earlier of one year from issuance or 45 days after FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance. Following these transactions, Moorhead holds 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 4,340 shares
Net Buy
3 txns
Insider
MOORHEAD DANIEL J
Role
Chief Financial Officer
Bought
13,020 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Series A Warrant F3, F1, F2 | 4,340 | -- | -- |
| Purchase | Series B Warrant F3, F1, F4 | 4,340 | -- | -- |
| Purchase | Common Stock | 4,340 | $5.76 | $25K |
Holdings After Transaction:
Series A Warrant — 4,340 shares (Direct);
Series B Warrant — 4,340 shares (Direct);
Common Stock — 4,340 shares (Direct)
Footnotes (4)
- F1. Exercisable immediately upon issuance
- F2. Expiration on the earlier of (i) the first anniversary of their issuance or (ii) the date that is 45 days following approval by the FDA of the Company's pending premarket approval supplement for LungFit PH II
- F3. Each Series A Warrant and Series B Warrant was purchased together with one share of common stock for a combined purchase price of $5.76.
- F4. 5 years following date of issuance
Key Figures
Common shares purchased: 4,340 shares
Series A Warrants purchased: 4,340 warrants
Series B Warrants purchased: 4,340 warrants
+3 more
6 metrics
Common shares purchased
4,340 shares
Shares of common stock purchased on 2026-07-29
Series A Warrants purchased
4,340 warrants
Series A Warrants acquired on 2026-07-29
Series B Warrants purchased
4,340 warrants
Series B Warrants acquired on 2026-07-29
Common stock purchase price
$5.76 per share
Price paid for common stock on 2026-07-29
Warrant exercise price
$5.51 per share
Exercise price for both Series A and Series B Warrants
Total securities purchased
13,020
Sum of common shares, Series A Warrants and Series B Warrants acquired
Key Terms
Series A Warrant, Series B Warrant, premarket approval supplement, LungFit PH II
4 terms
Series A Warrant financial
"Each Series A Warrant and Series B Warrant was purchased together with one share"
A Series A warrant is a contract issued alongside a company’s early funding round that gives the holder the right to buy a set number of shares later at a fixed price. Think of it like a coupon that lets an investor purchase stock at today’s agreed price even if the company’s value rises; it can boost potential upside for the warrant holder and create dilution for existing shareholders, so investors watch them when assessing ownership and future share value.
Series B Warrant financial
"Each Series A Warrant and Series B Warrant was purchased together with one share"
A Series B warrant is a tradable right issued alongside a Series B funding round that lets its holder buy a specified number of company shares at a fixed price for a set period. It matters to investors because exercising the warrant increases the total shares outstanding (dilution) and can be a cheap way to gain ownership if the company’s value rises — think of it like a coupon to buy stock later at today’s price.
premarket approval supplement medical
"the Company’s pending premarket approval supplement for LungFit PH II"
A premarket approval supplement is a regulatory submission seeking permission to change a medical device that already has FDA premarket approval, similar to asking a regulator for permission to alter a certified product before selling the new version. For investors, it matters because the supplement triggers a review that can affect how quickly a revised device reaches the market, add development or compliance costs, and change future sales or competitive positioning.
LungFit PH II medical
"approval by the FDA of the Company’s pending premarket approval supplement for LungFit PH II"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Beyond Air (XAIR)'s CFO buy in the latest Form 4 filing?
Beyond Air’s CFO Daniel J. Moorhead purchased 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants on 2026-07-29. All securities relate to Beyond Air common stock and are held directly after the transactions.
At what prices did the Beyond Air (XAIR) CFO acquire the stock and warrants?
The CFO bought common stock at $5.76 per share. Each Series A Warrant and Series B Warrant is exercisable for common stock at an exercise price of $5.51 per share, according to the filing details.
How many Beyond Air (XAIR) securities did the CFO buy in total?
Daniel J. Moorhead acquired 13,020 securities in total: 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants. All transactions were reported as purchases and result in direct ownership of these positions.
When do the Beyond Air (XAIR) Series A and Series B Warrants held by the CFO expire?
The Series A Warrants expire on the earlier of one year from issuance or 45 days after FDA approval of the LungFit PH II premarket approval supplement. The Series B Warrants expire five years after their issuance date.
When are the Beyond Air (XAIR) warrants purchased by the CFO exercisable?
The filing states the Series A and Series B Warrants are exercisable immediately upon issuance, each allowing the holder to acquire common stock at an exercise price of $5.51 per share, subject to their respective expiration terms.
Does the Beyond Air (XAIR) Form 4 indicate any 10b5-1 trading plan for the CFO’s purchases?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and no footnote describes these as plan-based trades. The reported transactions are simply characterized as purchases in open market or private transactions.